CLEC1B and neoplasm: While Etemad et al. 18 reported low plasma CLEC-2 levels across various tumor types, to our knowledge, our study is among the first to specifically demonstrate reduced plasma CLEC-2 levels in patients with breast cancer, with a particular focus on their association with clinicopathological features and survival outcomes.